Published in Cancer Res on April 10, 2013
Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget (2015) 1.62
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A (2015) 1.51
A molecular signature predictive of indolent prostate cancer. Sci Transl Med (2013) 1.32
Spatio-temporally precise activation of engineered receptor tyrosine kinases by light. EMBO J (2014) 1.05
Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol (2013) 1.04
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res (2013) 0.98
FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer. Virchows Arch (2014) 0.96
Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma. Am J Transl Res (2014) 0.88
Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics (2014) 0.86
miR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition. Oncotarget (2015) 0.83
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer (2015) 0.82
Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients. Oncogene (2015) 0.81
MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget (2016) 0.80
Type 2 Fibroblast Growth Factor Receptor Signaling Preserves Stemness and Prevents Differentiation of Prostate Stem Cells from the Basal Compartment. J Biol Chem (2015) 0.80
Fibroblast growth factors, old kids on the new block. Semin Cell Dev Biol (2016) 0.78
Overexpression of FGF9 in prostate epithelial cells augments reactive stroma formation and promotes prostate cancer progression. Int J Biol Sci (2015) 0.77
TGF-β induction of FGF-2 expression in stromal cells requires integrated smad3 and MAPK pathways. Am J Clin Exp Urol (2014) 0.77
Differential Roles of Carboxylated and Uncarboxylated Osteocalcin in Prostate Cancer Growth. J Cancer (2016) 0.76
Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy. Cancer Res Treat (2015) 0.75
A Versatile Gene Delivery System for Efficient and Tumor Specific Gene Manipulation in vivo. Discoveries (Craiova) (2016) 0.75
Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1. Drug Des Devel Ther (2016) 0.75
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Mol Cancer Ther (2017) 0.75
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995) 8.16
Metastatic prostate cancer in a transgenic mouse. Cancer Res (1996) 4.02
Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res (2002) 3.94
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 3.44
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
FGFR1 is required for the development of the auditory sensory epithelium. Neuron (2002) 2.35
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 2.14
FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals. EMBO J (2003) 1.85
Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res (1999) 1.80
Fgfr1 regulates patterning of the pharyngeal region. Genes Dev (2003) 1.53
Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol (2007) 1.46
Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development (2007) 1.38
Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene (2007) 1.28
Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate (2003) 1.27
Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res (2003) 1.18
Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol (1997) 1.15
Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch (2005) 0.97
FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer (2006) 0.96
Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. Prostate (2004) 0.95
The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest (2005) 0.95
Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis (1999) 0.88
Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors. Int J Cancer (2001) 0.86
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res (2002) 3.94
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 3.44
Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A (2011) 2.54
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res (2003) 2.47
Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res (2005) 2.44
Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res (2002) 2.22
Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res (2005) 2.14
Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions. J Infect Dis (2010) 2.12
COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature (2012) 2.11
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol (2004) 1.94
Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci U S A (2011) 1.94
Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res (2006) 1.90
Autophagy enhanced by microtubule- and mitochondrion-associated MAP1S suppresses genome instability and hepatocarcinogenesis. Cancer Res (2011) 1.81
C-C, C-O and C-N bond formation via rhodium(III)-catalyzed oxidative C-H activation. Chem Soc Rev (2012) 1.72
Transforming growth factor-beta1 induced myofibroblasts regulate LNCaP cell death. J Urol (2004) 1.65
FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep (2012) 1.63
Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol (2007) 1.62
Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal (2014) 1.61
Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res (2002) 1.57
Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res (2008) 1.56
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer (2006) 1.54
FRS2α-mediated FGF signals suppress premature differentiation of cardiac stem cells through regulating autophagy activity. Circ Res (2011) 1.52
Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol (2003) 1.50
Bmp signaling regulates myocardial differentiation from cardiac progenitors through a MicroRNA-mediated mechanism. Dev Cell (2010) 1.49
FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes (2007) 1.46
The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer (2012) 1.46
Importance of treatment institution in head and neck cancer radiotherapy. Otolaryngol Head Neck Surg (2009) 1.43
Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A (2013) 1.43
Autophagy in stem cells. Autophagy (2013) 1.43
Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development (2007) 1.38
Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest (2007) 1.35
Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem (2005) 1.35
Repressors of androgen and progesterone receptor action. J Biol Chem (2003) 1.35
Relaxin promotes prostate cancer progression. Clin Cancer Res (2007) 1.34
Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol (2007) 1.33
Fgf9 from dermal γδ T cells induces hair follicle neogenesis after wounding. Nat Med (2013) 1.33
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin (2013) 1.32
Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One (2012) 1.30
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
Correlations between controlled endotracheal tube cuff pressure and postprocedural complications: a multicenter study. Anesth Analg (2010) 1.28
Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate (2003) 1.27
Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia (2008) 1.26
RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res (2004) 1.25
Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology (2008) 1.24
Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res (2006) 1.24
The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer Res (2009) 1.21
Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res (2011) 1.21
Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. J Geriatr Psychiatry Neurol (2011) 1.21
Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex. Sci Transl Med (2012) 1.21
Microtubule-associated protein 1S (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation. J Biol Chem (2011) 1.20
Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther (2013) 1.20
Mesothelial- and epithelial-derived FGF9 have distinct functions in the regulation of lung development. Development (2011) 1.19
Generation of an Frs2alpha conditional null allele. Genesis (2007) 1.18
Frs2alpha-deficiency in cardiac progenitors disrupts a subset of FGF signals required for outflow tract morphogenesis. Development (2008) 1.16
Notch and TGFβ form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell (2012) 1.16
The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation (2011) 1.16
Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice. Am J Pathol (2002) 1.16
Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res (2004) 1.15
Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer (2008) 1.15
Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis. Development (2008) 1.13
Deletion of Frs2alpha from the ureteric epithelium causes renal hypoplasia. Am J Physiol Renal Physiol (2009) 1.12
Independent roles of Fgfr2 and Frs2alpha in ureteric epithelium. Development (2011) 1.11
Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol (2006) 1.10
Malignant advanced granulosa cell tumor of the adult testis: case report and review of the literature. Hum Pathol (2008) 1.09
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol (2010) 1.07
INPP4B: the new kid on the PI3K block. Oncotarget (2011) 1.07
Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res (2008) 1.07
Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res (2006) 1.07
Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol (2007) 1.06
Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog (2006) 1.06
Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology (2005) 1.06
Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis. Anticancer Drugs (2009) 1.05
Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog (2009) 1.05
Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Liver Int (2009) 1.04
Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One (2013) 1.04
FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol (2010) 1.03
Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors. Cancer Res (2003) 1.03